 Neoplasms, Plasma Cell
"Neoplasms, Plasma Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
| Descriptor ID |
D054219
|
| MeSH Number(s) |
C04.557.595
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Plasma Cell".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Plasma Cell".
This graph shows the total number of publications written about "Neoplasms, Plasma Cell" by people in UAMS Profiles by year, and whether "Neoplasms, Plasma Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 6 | 0 | 6 | | 2023 | 3 | 0 | 3 | | 2021 | 2 | 0 | 2 | | 2020 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2012 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasms, Plasma Cell" by people in Profiles over the past ten years.
-
Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, Balev M, Patwari A, Cheruvalath H, Bhutani D, Thanendrarajan S, Dhakal B, Zangari M, Al-Hadidi S, Cooper D, Lentzsch S, van Rhee F, D'Souza A, Szabo A, Schinke C, Chakraborty R. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024 Mar 05; 14(1):35.
-
Friend R, Atrash S. Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma. Transplant Cell Ther. 2024 Mar; 30(3):253-254.
-
Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, Al Hadidi S, Radhakrishnan SV, Narra R, Bhutani D, Thanendrarajan S, Janz S, Zangari M, Lentzsch S, Van Rhee F, Crescencio JCR, D'Souza A, Chakraborty R, Mohan M, Schinke C. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024 Mar 01; 109(3):906-914.
-
Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment. Haematologica. 2024 Mar 01; 109(3):777-786.
-
Steinhardt MJ, Truger M, Bittrich M, Zhou X, Noderer J, Riedhammer C, Xiao X, Gawlas S, Weis P, Eisele F, Haferlach C, Mersi J, Waldschmidt J, Einsele H, Rasche L, Kort?m KM. Venetoclax salvage therapy in relapsed/refractory multiple myeloma. Haematologica. 2024 Mar 01; 109(3):979-981.
-
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024 01 09; 8(1):251-259.
-
Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar; 204(3):887-891.
-
Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD, Zhan F, van Rhee F, Al Hadidi S. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023 07 11; 7(13):3069-3074.
-
Nahi H, Usmani SZ, Mateos MV, van de Donk NWCJ, Oriol A, Plesner T, Bandyopadhyay N, Hellemans P, Tromp B, Nnane I, Zemlickis D, Chari A, Moreau P. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leuk Lymphoma. 2023 02; 64(2):468-472.
-
Parikh R, Tariq SM, Marinac CR, Shah UA. A comprehensive review of the impact of obesity on plasma cell disorders. Leukemia. 2022 02; 36(2):301-314.
-
Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 02 01; 11(2):24.
-
Wyeth A, Gokden N, Alapat D, Zangari M, Pina-Oviedo S. Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma? Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e551-e555.
-
Abdallah AO, Bansal M, Kemp SA, Schichman SA, Xiang Z. A unique presentation of unilateral pleural effusion in a patient with a high-grade plasma cell neoplasm. Leuk Lymphoma. 2015; 56(10):2989-91.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|